S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).

Athanassios Argiris,Jieling Miao,Mihaela C. Cristea,Allen M. Chen,Jacob Sands,Roy H. Decker,Scott N. Gettinger,Megan E. Daly,Bryan A. Faller,Kathy S. Albain,Ronald Yanagihara,Linda L. Garland,Lauren Averett Byers,Ding Wang,Marianna Koczywas,Mary W. Redman,Karen Kelly,David R. Gandara

S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).

2019

Athanassios Argiris
Jieling Miao
Mihaela C. Cristea
Allen M. Chen
Jacob Sands
Roy H. Decker
Scott N. Gettinger
Megan E. Daly
Bryan A. Faller
Kathy S. Albain
Ronald Yanagihara
Linda L. Garland
Lauren Averett Byers
Ding Wang
Marianna Koczywas
Mary W. Redman
Karen Kelly
David R. Gandara

8523Background: Veliparib (V), a PARP inhibitor, may potentiate the antitumor effect of CRT in NSCLC. Methods: Eligibility included newly diagnosed unresectable stage III NSCLC. Patients were rando...

Keywords:

Placebo-controlled study
Chemoradiotherapy
PARP inhibitor
Stage III Non-Small Cell Lung Cancer
Stage III NSCLC
Internal medicine
Oncology
Pathology
Veliparib
Medicine
newly diagnosed
dose finding

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations